Can we use copeptin as a biomarker for masked hypertension or metabolic syndrome in obese children and adolescents?

Duygu DeligözoğluBelde Kasap-DemirCaner AlparslanHuriye ErbakGönül ÇatlıFatma MutlubaşDemet AlaygutEren SoyaltınSeçil Arslansoyu-ÇamlarÖnder Yavaşcan

Published in: Journal of pediatric endocrinology & metabolism : JPEM (2020)

Copeptin may be a beneficial biomarker to discriminate MHT, but not MS in obese children and adolescents. An insufficient BNP response to sodium intake might be one of the underlying causes of MHT in obese cases.

Keyphrases

metabolic syndrome
adipose tissue
weight loss
type diabetes
obese patients
insulin resistance
uric acid
mass spectrometry
bariatric surgery
multiple sclerosis
cardiovascular risk factors
ms ms
body mass index
arterial hypertension